胸腺肽α1防治局部晚期非小细胞肺癌同步放化疗患者放射性肺炎的疗效:一项2期临床试验(GASTO-1043)
这项2期单臂试验入组69例不可切除的局部晚期非小细胞肺癌患者,在同步放化疗期间及结束后2个月内每周给予胸腺肽α1,并按倾向性评分匹配选取69例同期未用胸腺肽α1的同步放化疗患者为对照。结果显示研究组G≥2级放射性肺炎发生率低于对照组(36.2% vs 53.6%,P=.040),G3~G4级淋巴细胞减少发生率更低(19.1% vs 62.1%,P<.001)。
要点
- 研究组G≥2级放射性肺炎发生率为36.2%,低于对照组的53.6%(P=.040)。
- 研究组G3~G4级淋巴细胞减少发生率为19.1%,低于对照组的62.1%(P<.001)。
- 研究组总淋巴细胞计数中位最低值为0.51 k/µL,高于对照组的0.30 k/µL(P<.001)。
核心结论
- 在同步放化疗期间及结束后给予胸腺肽α1,与局部晚期非小细胞肺癌患者G≥2级放射性肺炎和G3~G4级淋巴细胞减少的显著减少相关(对照为历史对照)。
研究设计与样本
- 这是一项2期单臂试验,入组年龄18至75岁、东部肿瘤协作组体能状态评分0至1分的不可切除局部晚期非小细胞肺癌患者。
- 研究组患者接受根治性同步放化疗,并自同步放化疗开始至结束后2个月每周给予胸腺肽α1。
- 对照组为同期接受同步放化疗但未接受胸腺肽α1干预的患者,经倾向性评分匹配方法选取。
- 研究组入组69例患者,另选取69例患者作为对照组。
主要发现
- 研究组G≥2级放射性肺炎发生率低于对照组(36.2% vs 53.6%,P=.040)。
- 对照组有2例(3.7%)发生G1级晚期肺纤维化,研究组无事件发生(P=.243)。
- 研究组G3~G4级淋巴细胞减少发生率低于对照组(19.1% vs 62.1%,P<.001)。
- 研究组总淋巴细胞计数中位最低值高于对照组(0.51 k/µL vs 0.30 k/µL,P<.001)。
- 研究组最大C反应蛋白≥100 mg/L的患者比例低于对照组(13.8% vs 29.7%,P=.029)。
关键数值与推荐
- 放疗第一程为51 Gy分17次每日照射,或40 Gy分10次每日照射,之后重新评估,无疾病进展者接受自适应计划推量15 Gy分5次每日照射或24 Gy分6次每日照射。
- 同步化疗为放疗期间每周给予多西他赛25 mg/m2和奈达铂25 mg/m2。
- 主要终点为G≥2级放射性肺炎的发生率。
- 次要终点包括晚期肺纤维化发生率、总淋巴细胞计数、血清C反应蛋白水平及肠道微生物群组成。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy of thymosin α1 in management of radiation pneumonitis (RP) in patients with locally advanced non-small cell lung cancer (LANSCLC) treated with concurrent chemoradiotherapy (CCRT). METHODS AND MATERIALS: This phase 2, single-arm trial enrolled patients with unresectable LANSCLC of 18 to 75 years' old and an Eastern Cooperative Oncology Group performance status of 0 to 1. Eligible patients received definitive CCRT and weekly thymosin α1 from the start of CCRT until 2 months after CCRT. Patients were administered 51 Gy in 17 daily fractions or 40 Gy in 10 daily fractions in the first course followed by a re-evaluation and those patients without disease progression had an adaptive plan of 15 Gy in 5 daily fractions or 24 Gy in 6 daily fractions as a boost. Concurrent chemotherapy consisted of weekly docetaxel (25 mg/m2) and nedaplatin (25 mg/m2) during radiation therapy. The primary endpoint was the incidence of Grade (G) ≥2 RP. Secondary endpoints included the incidence of late pulmonary fibrosis, total lymphocyte count (TLC), serum C-reactive protein (CRP) levels, and the composition of gut microbiota. TLC and CRP data were collected at baseline, 2 to 3 weeks during CCRT, the end of CCRT, 2 and 6 months after CCRT. Fecal samples were collected at baseline and the end of CCRT. Patients treated with CCRT but without thymosin α1 intervention during the same period were selected as the control group by the propensity score matching method. RESULTS: Sixty-nine patients were enrolled in the study, and another 69 patients were selected as the control group. The incidence of G≥2 RP was lower in the study group compared with control cases (36.2% vs 53.6%, P = .040). G1 late pulmonary fibrosis occurred in 2 (3.7%) patients of the control group compared with no event in the study group (P = .243). Compared with the control group, the incidence of G3 to G4 lymphopenia (19.1% vs 62.1%, P < .001) was lower, and the median TLC nadir (0.51 k/µL vs 0.30 k/µL, P < .001) was higher in the study group. The proportion of patients with maximum CRP ≥100 mg/L was lower in the study group (13.8% vs 29.7% P = .029). The diversity and community composition of the gut microbiota were not significantly different between the 2 groups. CONCLUSIONS: Administration of thymosin α1 during and after CCRT was associated with significant reductions in G≥2 RP and G3 to G4 lymphopenia in patients with LANSCLC compared with historic controls.
引用
- Liu F, Qiu B, Xi Y, et al. Efficacy of Thymosin α1 in Management of Radiation Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiotherapy: A Phase 2 Clinical Trial (GASTO-1043). Int J Radiat Oncol Biol Phys. 2022. PMID: 35870709. doi:10.1016/j.ijrobp.2022.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。